NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

GM2神經節苷脂症:流行病學洞察(2030年為止的預測)

GM2 Gangliosidosis - Epidemiology Insight - 2030

出版商 DelveInsight Business Research LLP 商品編碼 966781
出版日期 按訂單生產 內容資訊 英文 100 Pages
商品交期: 10個工作天內
價格
GM2神經節苷脂症:流行病學洞察(2030年為止的預測) GM2 Gangliosidosis - Epidemiology Insight - 2030
出版日期: 按訂單生產內容資訊: 英文 100 Pages
簡介

本報告提供世界主要7個國家(美國,歐洲5個國家(德國,法國,義大利,西班牙,英國),日本)的GM2神經節苷脂症的相關調查,提供流行病學及預測,各市場區隔的病例,診斷案例等資訊。

目錄

第1章 主要洞察

第2章 摘要整理

第3章 疾病的背景和概要

  • 概要
  • 徵兆與症狀
  • 病理學
  • 危險因素
  • 診斷

第4章 患者的治療過程

第5章 流行病學和患者人口

  • 流行病學的主要調查結果
  • 前提條件與理論性根據:主要7個國家
  • 流行病學方案:主要7個國家
    • 流行病學方案(2017-2030)
  • 美國流行病學
  • 歐洲5國流行病學
    • 德國流行病學
    • 法國流行病學
    • 義大利流行病學
    • 西班牙流行病學
    • 英國流行病學
  • 日本流行病學

第6章 治療流程,目前治療,及醫務

  • 治療和管理
  • 治療流程

第7章 KOL的見解

第8章 未滿足需求

第9章 附錄

  • 參考文件
  • 報告的調查手法

第10章 DelveInsight的服務內容

第11章 免責聲明

第12章 關於DelveInsight

目錄
Product Code: DIEI1056

DelveInsight's 'GM2 Gangliosidosis - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted GM2 Gangliosidosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

GM2 Gangliosidosis Understanding

The DelveInsight GM2 Gangliosidosis epidemiology report gives a thorough understanding of the GM2 Gangliosidosis by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for GM2 Gangliosidosis in the US, Europe, and Japan. The report covers the detailed information of the GM2 Gangliosidosis epidemiology scenario in seven major countries (US, EU5, and Japan).

GM2 Gangliosidosis Epidemiology Perspective by DelveInsight

The GM2 Gangliosidosis epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The GM2 Gangliosidosis epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The GM2 Gangliosidosis epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

GM2 Gangliosidosis Detailed Epidemiology Segmentation

The GM2 Gangliosidosis epidemiology covered in the report provides historical as well as forecasted GM2 Gangliosidosis epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight GM2 Gangliosidosis report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report:

  • The GM2 Gangliosidosis report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The GM2 Gangliosidosis Epidemiology Report and Model provide an overview of the risk factors and global trends of GM2 Gangliosidosis in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of GM2 Gangliosidosis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of GM2 Gangliosidosis
  • The report provides the segmentation of the GM2 Gangliosidosis epidemiology

Report Highlights:

  • 11-Year Forecast of GM2 Gangliosidosis epidemiology
  • 7MM Coverage
  • Total Cases of GM2 Gangliosidosis
  • Total Cases of GM2 Gangliosidosis according to segmentation
  • Diagnosed cases of GM2 Gangliosidosis

KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to GM2 Gangliosidosis ?
  • What are the key findings pertaining to the GM2 Gangliosidosis epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of GM2 Gangliosidosis across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the GM2 Gangliosidosis ?
  • What are the currently available treatments of GM2 Gangliosidosis ?

Reasons to buy:

  • The GM2 Gangliosidosis Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global GM2 Gangliosidosis market
  • Quantify patient populations in the global GM2 Gangliosidosis market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for GM2 Gangliosidosis therapeutics in each of the markets covered
  • Understand the magnitude of GM2 Gangliosidosis population by its epidemiology
  • The GM2 Gangliosidosis Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Executive Summary of GM2 Gangliosidosis

3. GM2 Gangliosidosis : Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Sign and Symptoms
  • 3.3. Pathophysiology
  • 3.4. Risk Factors
  • 3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

  • 5.1. Epidemiology Key Findings
  • 5.2. Assumptions and Rationale: 7MM
  • 5.3. Epidemiology Scenario: 7MM
    • 5.3.1. GM2 Gangliosidosis Epidemiology Scenario in the 7MM (2017- 2030)
  • 5.4. United States Epidemiology
    • 5.4.1. GM2 Gangliosidosis Epidemiology Scenario in the United States (2017- 2030)
  • 5.5. EU-5 Country-wise Epidemiology
    • 5.5.1. Germany Epidemiology
      • 5.5.1.1. GM2 Gangliosidosis Epidemiology Scenario in Germany (2017- 2030)
    • 5.5.2. France Epidemiology
      • 5.5.2.1. GM2 Gangliosidosis Epidemiology Scenario in France (2017- 2030)
    • 5.5.3. Italy Epidemiology
      • 5.5.3.1. GM2 Gangliosidosis Epidemiology Scenario in Italy (2017- 2030)
    • 5.5.4. Spain Epidemiology
      • 5.5.4.1. GM2 Gangliosidosis Epidemiology Scenario in Spain (2017- 2030)
    • 5.5.5. United Kingdom Epidemiology
      • 5.5.5.1. GM2 Gangliosidosis Epidemiology Scenario in the United Kingdom (2017-2030)
  • 5.6. Japan Epidemiology
    • 5.6.1. GM2 Gangliosidosis Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

  • 6.1. GM2 Gangliosidosis Treatment and Management
  • 6.2. GM2 Gangliosidosis Treatment Algorithm

7. KOL Views

8. Unmet Needs

9. Appendix

  • 9.1. Bibliography
  • 9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

The table of contents is not exhaustive; will be provided in the final report

List of Tables

  • Table 1: GM2 Gangliosidosis Epidemiology in 7MM (2017-2030)
  • Table 2: GM2 Gangliosidosis Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Table 3: GM2 Gangliosidosis Epidemiology in the United States (2017-2030)
  • Table 4: GM2 Gangliosidosis Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5: GM2 Gangliosidosis Epidemiology in Germany (2017-2030)
  • Table 6: GM2 Gangliosidosis Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7: GM2 Gangliosidosis Epidemiology in France (2017-2030)
  • Table 8: GM2 Gangliosidosis Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9: GM2 Gangliosidosis Epidemiology in Italy (2017-2030)
  • Table 10: GM2 Gangliosidosis Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11: GM2 Gangliosidosis Epidemiology in Spain (2017-2030)
  • Table 12: GM2 Gangliosidosis Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13: GM2 Gangliosidosis Epidemiology in the United Kingdom (2017-2030)
  • Table 14: GM2 Gangliosidosis Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Table 15: GM2 Gangliosidosis Epidemiology in Japan (2017-2030)
  • Table 16: GM2 Gangliosidosis Diagnosed and Treatable Cases in Japan (2017-2030)

List of Figures

  • Figure 1: GM2 Gangliosidosis Epidemiology in 7MM (2017-2030)
  • Figure 2: GM2 Gangliosidosis Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Figure 3: GM2 Gangliosidosis Epidemiology in the United States (2017-2030)
  • Figure 4: GM2 Gangliosidosis Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5: GM2 Gangliosidosis Epidemiology in Germany (2017-2030)
  • Figure 6: GM2 Gangliosidosis Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7: GM2 Gangliosidosis Epidemiology in France (2017-2030)
  • Figure 8: GM2 Gangliosidosis Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9: GM2 Gangliosidosis Epidemiology in Italy (2017-2030)
  • Figure 10: GM2 Gangliosidosis Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11: GM2 Gangliosidosis Epidemiology in Spain (2017-2030)
  • Figure 12: GM2 Gangliosidosis Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13: GM2 Gangliosidosis Epidemiology in the United Kingdom (2017-2030)
  • Figure 14: GM2 Gangliosidosis Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Figure 15: GM2 Gangliosidosis Epidemiology in Japan (2017-2030)
  • Figure 16: GM2 Gangliosidosis Diagnosed and Treatable Cases in Japan (2017-2030)

The table of contents is not exhaustive; will be provided in the final report